z-logo
Premium
Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
Author(s) -
Nishikawa Go,
Booth Christopher,
Prasad Vinay
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32979
Subject(s) - olaparib , medicine , pancreatic cancer , cancer , clinical trial , oncology , polymerase , poly adp ribose polymerase , gene , biochemistry , chemistry
Because of the lack of a survival benefit, the suboptimal control arm design, and the overall health care costs, the authors do not believe that olaparib represents a major advance for patients with pancreatic cancer. The POLO trial illustrates that as a community, even in settings where there is a huge need, physicians must be rigorous in their methodology and mindful that they not lower the bar for new therapies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here